Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Stocks in this Quantisnow insightHealth Care
Historical context for ELVN
Across the 4 sessions after earlier ELVN headlines, the stock closed higher 0 times and lower 4 times, with a median move of 8.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ELVN | SPY |
|---|---|---|---|
| Dec 12, 2025 | Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules | -10.2% | -1.1% |
| Dec 11, 2025 | Enliven Therapeutics Announces New CEO to Drive Next Phase of Development | -6.9% | +0.2% |
| Nov 13, 2025 | /C O R R E C T I O N -- Enliven Therapeutics, Inc./and 1 other headline that session | -0.1% | -1.7% |
| Nov 3, 2025 | Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting | -14.6% | +0.2% |
Quantisnow market dataNASDAQ
ELVN
Enliven Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for ELVN
Full ELVN profile on Quantisnow Follow ELVN and get a push notification the moment its next story breaks.